ASMB
ASSEMBLY BIOSCIENCES, INC.
NASDAQ · Healthcare · Biotechnology · US
$20.20
+0.20%Year over year
Reported trailing growth
- Revenue
- +125.1%
- EBITDA
- +100.2%
- EBIT
- +79.8%
- EPS
- +109.6%
- Free cash flow
- +30.9%
- Operating cash flow
- +31.1%
Forward estimates
Based on analyst estimates
- Revenue
- -22.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +217.7%
- EBITDA
- +84.9%
- EBIT
- +73.3%
- Net income
- +84.8%
- EPS
- +91.8%
- Free cash flow
- +19.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026